Aim: To obtain the variable region gene sequence of heavy and light chain of mouse anti-human BAFF monoclonal antibody (mAb) on base of BAFF mAb which was cloned in our laboratory.
Methods: The total RNA was extracted from mouse anti-human BAFF mAb hybridoma cell line FMMUB(4);, and then the RNA was reverse transcribed into cDNA. Specific primers were designed to amplify the targeted gene. The targeted gene fragments were inserted into vectors to construct the clone vectors. The gene sequences were analyzed after identified by positive clones screening and restrictive enzyme digestion.
Results: The variable region gene sequences of mouse anti-human BAFF mAb were obtained.
Conclusion: The variable region gene sequences of mouse anti-human BAFF mAb will provide experimental basis for further study on constructing engineered antibodies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Preparation and identification of monoclonal antibodies against human LAG3 by immunizing mice with recombinant eukaryotic cell antigens].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
December 2024
Department of Medical Experimental Center, Northern Jiangsu People's Hospital, Yangzhou 225001, China. *Corresponding author, E-mail: yyue_king
Objective To prepare mouse anti-human lymphocyte activation gene 3 (LAG3) monoclonal antibody (mAb) and perform immunological identification of the antibody. Methods BALB/c mice were immunized with LAG3-mLumin-3T3 cells, which stably express the extracellular and transmembrane regions of human LAG3 in mouse 3T3 cells. The secretion of anti-human LAG3 antibodies in mouse serum was assessed using flow cytometry and immunofluorescence.
View Article and Find Full Text PDFAn antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control.
Nat Commun
December 2024
Key Laboratory of Immune Response and Immunotherapy, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Scienes, Guangzhou, China.
CD73, an ectoenzyme responsible for adenosine production, is often elevated in immuno-suppressive tumor environments. Inhibition of CD73 activity holds great promise as a therapeutic strategy for CD73-expressing cancers. In this study, we have developed a therapeutic anti-human CD73 antibody cocktail, HB0045.
View Article and Find Full Text PDFVectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy.
Hum Gene Ther
December 2024
Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA.
Chronic hypereosinophilia, defined as persistent elevated blood levels of eosinophils ≥1,500/μL, is associated with tissue infiltration of eosinophils and consequent organ damage by eosinophil release of toxic mediators. The current therapies for chronic hypereosinophilia have limited success, require repetitive administration, and are associated with a variety of adverse effects. As a novel approach to treat chronic hypereosinophilia, we hypothesized that adeno-associated virus (AAV)-mediated delivery of an anti-human eosinophil antibody would provide one-time therapy that would mediate persistent suppression of blood eosinophil levels.
View Article and Find Full Text PDFInduction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137.
Oncoimmunology
December 2025
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Regulatory T cells (Tregs) contribute significantly to the immunosuppressive nature of the tumor microenvironment which is a main barrier for immunotherapies of solid cancers. Reducing Treg numbers enhances anti-tumor immune responses but current depletion strategies also impair effector T cells (Teffs), potentially leading to reduced anti-tumor immunity and/or autoimmune diseases. CD137 has been identified as the most differentially expressed gene between peripheral Tregs and intratumoral Tregs in virtually all solid cancers.
View Article and Find Full Text PDFDevelopment and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.
J Nanobiotechnology
December 2024
Precirix, Burg. Etienne Demunterlaan 3, Brussels, Matthias, B-1090, Belgium.
Background: Folate receptor alpha (FRα) overexpression is seen in many cancers. Radioligand therapy (RLT) has emerged as a promising tool to target FRα and has been investigated previously, but further progression was limited due to high kidney retention and, subsequently, toxicity. To circumvent this, we present here the development of a [I]I-GMIB-conjugated anti-human FRα (hFRα) single-domain antibody (sdAb), with intrinsically fast renal clearance and concomitant low kidney retention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!